rfhealthЗдравоохранение Российской ФедерацииHealth care of the Russian Federation0044-197X2412-0723Federal Scientific Center of Hygiene named after F.F. Erisman10.47470/0044-197X-2022-66-6-549-554rfhealth-1028Research ArticleНАМ ПИШУТLETTERS TO EDITORТаргетная биопсия предстательной железы под контролем гистосканированияHistoscan-guided targeted biopsy of the prostatehttps://orcid.org/0000-0001-6390-3408КимЮрий АлександровичKimYuriy A.

Аспирант каф. урологии Московского государственного медико-стоматологического университета им. А.И. Евдокимова, 127473, Москва.

e-mail: dockimyura@gmail.com

Department of Urology Resident, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, 127473, Russian Federation.

e-mail: dockimyura@gmail.com 

dockimyura@gmail.comhttps://orcid.org/0000-0003-3299-0574ГоворовА. В.GovorovAleksandr V.noemail@neicon.ruhttps://orcid.org/0000-0001-5468-0011ВасильевА. О.VasilyevAleksandr O.noemail@neicon.ruhttps://orcid.org/0000-0002-6096-5723ПушкарьД. Ю.PushkarDmitry Yu.noemail@neicon.ruhttps://orcid.org/0000-0003-3107-3731ХатьковИ. Е.KhatkovIgor E.noemail@neicon.ruФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской Федерации; ГБУЗ города Москвы «Городская клиническая больница имени С.И. Спасокукоцкого Департамента здравоохранения города Москвы»РоссияA.I. Evdokimov Moscow State University of Medicine and Dentistry; Municipal Clinical Hospital named after. S.I. Spasokukotsky, Moscow City Health DepartmentRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской Федерации; ГБУЗ города Москвы «Городская клиническая больница имени С.И. Спасокукоцкого Департамента здравоохранения города Москвы»; ГБУ города Москвы «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения города Москвы»РоссияA.I. Evdokimov Moscow State University of Medicine and Dentistry; Municipal Clinical Hospital named after. S.I. Spasokukotsky, Moscow City Health Department; Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentRussian FederationФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Министерства здравоохранения Российской ФедерацииРоссияA.I. Evdokimov Moscow State University of Medicine and DentistryRussian Federation202212122022666549554Copyright © Ким Ю.А., Говоров А.В., Васильев А.О., Пушкарь Д.Ю., Хатьков И.Е., 20222022Ким Ю.А., Говоров А.В., Васильев А.О., Пушкарь Д.Ю., Хатьков И.Е.Kim Y.A., Govorov A.V., Vasilyev A.O., Pushkar D.Y., Khatkov I.E.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rfhealth.ru/jour/article/view/1028Введение

Введение. Рак предстательной железы (РПЖ) является вторым наиболее часто диагностируемым злокачественным новообразованием у мужчин. Развитие медицинских технологий привело к модернизации современных методов визуализации, позволив внедрить новый минимально инвазивный метод диагностики рака — гистосканирование простаты. Гистосканирование — это инновационный метод визуализации, который способен дифференцировать доброкачественные и злокачественные области в пределах исследуемой ткани. А с помощью нового программного обеспечения «True Targeting», возможно выполнение «таргетной» биопсии в режиме реального времени.

Цель исследования — определить эффективность и безопасность выполнения таргетной биопсии простаты под контролем гистосканирования.

Материал и методы

Материал и методы. Нами проведено проспективное исследование с включением данных 2501 пациента, проходившего обследование в клинике урологии МГМСУ им. А.И. Евдокимова на базе ГБУЗ ГКБ им. С.И. Спасокукоцкого.

Результаты

Результаты. Средний возраст пациентов составил 66 лет, уровень общего простатического специфического антигена — 14,39 нг/мл, объём предстательной железы по данным ТРУЗИ — 54,43 см3. Общая частота выявления РПЖ составила 53,38%, при биопсии из 12 точек — 52,1%, при таргетной биопсии — 37,58%. Среди осложнений биопсии наиболее часто (33% случаев) отмечена гемоспермия (Clavien–Dindo — I степень), в 15% случаев — гематурия (Clavien–Dindo — I–II степень). Серьёзных осложнений не выявлено.

Ограничения исследований

Ограничения исследований. В качестве ограничений выделены: биопсия предстательной железы — предмет, 2501 пациент — количественный параметр, пациенты с подозрением на РПЖ — качественный показатель.

Заключение

Заключение. Выполнение биопсии простаты под контролем гистосканирования безопасно, эффективно, в связи с чем имеет большой потенциал в диагностике РПЖ, поскольку помогает как в выборе метода лечения, так и в планировании хода дальнейшей операции.

Соблюдение этических стандартов. Исследование одобрено Межвузовским комитетом по этике г. Москва, выписка из протокола №12-20 от 19.11.2020. Все пациенты подписывали информированное согласие на участие в исследование.

Участие авторов

Участие авторов: Ким Ю.А. — сбор и обработка материала, написание текста; Говоров А.В. — концепция и дизайн исследования, редактирование; Васильев А.О. — концепция и дизайн исследования, редактирование; Пушкарь Д.Ю. — концепция и дизайн исследования; Хатьков И.Е. — концепция и дизайн исследования. Все соавторы — утверждение окончательного варианта статьи, ответственность за целостность всех частей статьи.

Финансирование

Финансирование. Исследование не имело спонсорской поддержки.

Конфликт интересов

Конфликт интересов. Авторы декларируют отсутствие явных и потенциальных конфликтов интересов в связи с публикацией данной статьи.

Поступила 18

Поступила 18.07.2022Принята в печать 07.09.2022Опубликована 12.12.2022

Introduction

Introduction. Prostate cancer is the second most commonly diagnosed malignant neoplasm in men. The development of technologies requires the study of advanced research methods, an extraordinary, new limited-invasive method for diagnosing cancer — histoscanning of the prostate. Histoscan is an innovative imaging technique that is potent of differentiating between benign and malignant areas within the examined prostate tissue. With the new “True Targeting” software, it is possible to perform a “targeted” biopsy in real time. 

Purpose

Purpose. To determine the efficacy and safety of performing histoscan-guided targeted biopsy of the prostate.

Materials and methods

Materials and methods. The prospective study with the inclusion of data from 2501 patients examined at the Clinic of urology of the Moscow State Medical University named after A.I. Evdokimov at the Municipal Clinical Hospital named after S.I. Spasokukotsky.

Results

Results. The average age of the patients was 66 years, the level of prostate specific antigen was about 14,39 ng/ml, the volume of the prostate was 54,43 cm3. The overall incidence of prostate cancer was 53,38%, with a biopsy of 12 points — 52,1%, while with a targeted biopsy— 37,58%. Among the biopsy complications, hemospermia (Clavien–Dindo — I) was most often (33% of cases), hematuria (Clavien–Dindo — I–II) in 15% of cases. No serious complications were identified.

Limitations

Limitations. As restrictions, the following were identified: prostate biopsy-subject, 2501 patients — a quantitative parameter, patients with suspected prostate cancer — a qualitative indicator.

Conclusion

Conclusion. The published results of the study showed that histoscan-guided biopsy ofthe prostate is safe, effective, and therefore has alarge potential in cancer diagnosis, as it helps both in choosing a treatment method and in planning the course of further surgery.

Compliance with ethical standards. The study was approved by the Interuniversity Ethics Committee of Moscow, extract from protocol No. 12-20, dated 11.19.2020. All patients signed an informed consent to participate in the study.

Contribution of the authors: Kim Yu.A. — material collection and processing, writing the text; Govorov A.V. — research concept and design, editing; Vasilyev A.O. — research concept and design, editing; Pushkar D.Yu. — research concept and design; Khatkov I.E. — research concept and design. All authors are responsible for the integrity of all parts of the manuscript and approval of the manuscript final version.

Acknowledgment

Acknowledgment. The study had no sponsorship.

Conflict of interest

Conflict of interest. The authors declare no conflict of interest.

Received

Received: July 18, 2022 Accepted: September 07, 2022Published: December 12, 2022

рак предстательной железыскрининггистосканированиебиопсия предстательной железыprostate cancerscreeninghistoscanningprostate biopsyReferencesSung H., Ferlay J., Siegel R.L., Laversanne M.L., Soerjomataram I., Jemal A., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71(3): 209-49. https://doi.org/10.3322/caac.21660Sung H., Ferlay J., Siegel R.L., Laversanne M.L., Soerjomataram I., Jemal A., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71(3): 209–49. https://doi.org/10.3322/caac.21660Васильев А.О., Прилепская Е.А., Ковылина М.В., Говоров А.В., Садченко А.В., Сидоренков А.В. и др. Современные маркеры и гистологические особенности рака предстательной железы. Урология. 2016; (6): 164-6Vasil’ev A.O., Prilepskaya E.A., Kovylina M.V., Govorov A.V., Sadchenko A.V., Sidorenkov A.V., et al. Contemporary markers and histological features of prostate cancer. Urologiya. 2016; (6): 164–6. (in Russian)Smeenge M., de la Rosette J.J., Wijkstra H. Current status of transrectal ultrasound techniques in prostate cancer. Curr. Opin. Urol. 2012; 22(4): 297-302. https://doi.org/10.1097/MOU.0b013e3283548154Smeenge M., de la Rosette J.J., Wijkstra H. Current status of transrectal ultrasound techniques in prostate cancer. Curr. Opin. Urol. 2012; 22(4): 297–302. https://doi.org/10.1097/MOU.0b013e3283548154Loeb S., Vellekoop A., Ahmed H.U., Catto J., Emberton M., Nam R., et al. Systematic review of complications of prostate biopsy. Eur. Urol. 2013; 64(6): 876-92. https://doi.org/10.1016/j.eururo.2013.05.049Loeb S., Vellekoop A., Ahmed H.U., Catto J., Emberton M., Nam R., et al. Systematic review of complications of prostate biopsy. Eur. Urol. 2013; 64(6): 876–92. https://doi.org/10.1016/j.eururo.2013.05.049Braeckman J., Autier P., Soviany C., Nir R., Nir D., Michielsen D., et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008; 102(11): 1560-5. https://doi.org/10.1111/j.1464-410X.2008.07878.xBraeckman J., Autier P., Soviany C., Nir R., Nir D., Michielsen D., et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int. 2008; 102(11): 1560–5. https://doi.org/10.1111/j.1464-410X.2008.07878.xBraeckman J., Autier P., Garbar C., Marichal M.P., Soviany C., Nir R., et al.Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008; 101(3): 293-8. https://doi.org/10.1111/j.1464-410X.2007.07232.xBraeckman J., Autier P., Garbar C., Marichal M.P., Soviany C., Nir R., et al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int. 2008; 101(3): 293–8. https://doi.org/10.1111/j.1464-410X.2007.07232.xMacek P., Barret E., Sanchez-Salas R., Galiano M., Rozet F., Ahallal Y., et al. Prostate histoscanning in clinically localized biopsy proven prostate cancer - an accuracy study. J. Endourol. 2014; 28(3): 371-6. https://doi.org/10.1089/end.2013.0419Macek P., Barret E., Sanchez-Salas R., Galiano M., Rozet F., Ahallal Y., et al. Prostate histoscanning in clinically localized biopsy proven prostate cancer – an accuracy study. J. Endourol. 2014; 28(3): 371–6. https://doi.org/10.1089/end.2013.0419Chen F.K., de Castro Abreu A.L., Palmer S.L. Utility of ultrasound in the diagnosis, treatment, and follow-up of prostate cancer: state of the art. J. Nucl. Med. 2016; 57(3): 13-8. https://doi.org/10.2967/jnumed.116.177196Chen F.K., de Castro Abreu A.L., Palmer S.L. Utility of ultrasound in the diagnosis, treatment, and follow-up of prostate cancer: state of the art. J. Nucl. Med. 2016; 57(3): 13–8. https://doi.org/10.2967/jnumed.116.177196Rouviere O., Melodelima C., Dinh Au.H., Bratan F., Pagnoux G., Sanzalone T., et al. Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study. Eur. Radiol. 2017; 27(5): 1858-66. https://doi.org/10.1007/s00330-016-4534-9Rouviere O., Melodelima C., Dinh Au.H., Bratan F., Pagnoux G., Sanzalone T., et al. Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study. Eur. Radiol. 2017; 27(5): 1858–66. https://doi.org/10.1007/s00330-016-4534-9Mannaerts C.K., Wildeboer R., Remmers S., van Kollenburg R.A., Kajtazovic A., Hagemannet J., et al. Multiparametric ultrasound for prostate cancer detection and localization: correlation of b-mode, shear wave elastography and contrast enhanced ultrasound with radical prostatectomy specimens. J. Urol. 2019; 202(6): 1166-73. https://doi.org/10.1097/JU.0000000000000415Mannaerts C.K., Wildeboer R., Remmers S., van Kollenburg R.A., Kajtazovic A., Hagemannet J., et al. Multiparametric ultrasound for prostate cancer detection and localization: correlation of b-mode, shear wave elastography and contrast enhanced ultrasound with radical prostatectomy specimens. J. Urol. 2019; 202(6): 1166–73. https://doi.org/10.1097/JU.0000000000000415Abouassaly R., Klein E.A., El-Shefai A., Stephenson A. Impact of using 29 MHz high-resolution micro-ultrasound in real-time targeting of transrectal prostate biopsies: initial experience. World J. Urol. 2020; 38(5): 1201-6. https://doi.org/10.1007/s00345-019-02863-yAbouassaly R., Klein E.A., El-Shefai A., Stephenson A. Impact of using 29 MHz high-resolution micro-ultrasound in real-time targeting of transrectal prostate biopsies: initial experience. World J. Urol. 2020; 38(5): 1201–6. https://doi.org/10.1007/s00345-019-02863-yНазаренко Г.И., Хитрова А.Н. Ультразвуковая диагностика предстательной железы в современной урологической практике. М.: Видар-М; 2012Nazarenko G.I., Khitrova A.N. Ultrasound Diagnosis of Prostate in Modern Urological Practice [Ul’trazvukovaya diagnostika predstatel’noy zhelezy v sovremennoy urologicheskoy praktike]. Moscow: Vidar-M; 2012. (in Russian)Ismail M., Petersen R.O., Alexander A.A., Newschaffer C., Gomella L.G. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology. 1997; 50(6): 906-12. https://doi.org/10.1016/S0090-4295(97)00403-2Ismail M., Petersen R.O., Alexander A.A., Newschaffer C., Gomella L.G. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology. 1997; 50(6): 906–12. https://doi.org/10.1016/S0090-4295(97)00403-2Rohrbach D., Wodlinger B., Wen J., Mamoa J., Feleppa E. High-frequency quantitative ultrasound for imaging prostate cancer using a novel micro-ultrasound scanner. Ultrasound Med. Biol. 2018; 44(7): 1341-54. https://doi.org/10.1016/j.ultrasmedbio.2018.02.014Rohrbach D., Wodlinger B., Wen J., Mamoa J., Feleppa E. High-frequency quantitative ultrasound for imaging prostate cancer using a novel micro-ultrasound scanner. Ultrasound Med. Biol. 2018; 44(7): 1341–54. https://doi.org/10.1016/j.ultrasmedbio.2018.02.014Ghai S., Eure G., Fradet V., Hyndman M.E., McGrath T., Wodlinger B., et al. Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification. J. Urol. 2016; 196(2): 562-9. https://doi.org/10.1016/j.juro.2015.12.093Ghai S., Eure G., Fradet V., Hyndman M.E., McGrath T., Wodlinger B., et al. Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification. J. Urol. 2016; 196(2): 562–9. https://doi.org/10.1016/j.juro.2015.12.093Ghai S., Van der Kwast T. Suspicious findings on micro-ultrasound imaging and early deection of prostate cancer. Urol. Case Rep. 2018; 16: 98-100. https://doi.org/10.1016/j.eucr.2017.11.013Ghai S., Van der Kwast T. Suspicious findings on micro-ultrasound imaging and early deection of prostate cancer. Urol. Case Rep. 2018; 16: 98–100. https://doi.org/10.1016/j.eucr.2017.11.013Aigner F., Pallwein L., Junker D., Schäfer G., Mikuz G., Pedross F., et al. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4,00 ng/ml or less. J. Urol. 2010; 184(3): 913-7. https://doi.org/10.1016/j.juro.2010.05.026Aigner F., Pallwein L., Junker D., Schäfer G., Mikuz G., Pedross F., et al. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4,00 ng/ml or less. J. Urol. 2010; 184(3): 913–7. https://doi.org/10.1016/j.juro.2010.05.026Fütterer J.J., Briganti A., De Visschere P., Emberton M., Giannarini G., Kirkham A., et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging. A systematic review of the literature? Eur. Urol. 2015; 68(6): 1045-53. https://doi.org/10.1016/j.eururo.2015.01.013Fütterer J.J., Briganti A., De Visschere P., Emberton M., Giannarini G., Kirkham A., et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging. A systematic review of the literature? Eur. Urol. 2015; 68(6): 1045–53. https://doi.org/10.1016/j.eururo.2015.01.013Thompson J.E., van Leeuwen P.J., Moses D., Shnier R., Brenner P., Delprado W., et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J. Urol. 2016; 195(5): 1428-35. https://doi.org/10.1016/j.juro.2015.10.140Thompson J.E., van Leeuwen P.J., Moses D., Shnier R., Brenner P., Delprado W., et al. The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J. Urol. 2016; 195(5): 1428–35. https://doi.org/10.1016/j.juro.2015.10.140Pokorny M.R., de Rooij M., Duncan E., Schröder F.H., Parkinson R., Barentsz J.O., et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur. Urol. 2014; 66(1): 22-9. https://doi.org/10.1016/j.eururo.2014.03.002Pokorny M.R., de Rooij M., Duncan E., Schröder F.H., Parkinson R., Barentsz J.O., et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur. Urol. 2014; 66(1): 22–9. https://doi.org/10.1016/j.eururo.2014.03.002Wegelin O., van Melick H.H., Hooft L., Bosch J.R., Reitsma H.B., Barentsz J.O., et al.Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur. Urol. 2017; 71(4): 517-31. https://doi.org/10.1016/j.eururo.2016.07.041Wegelin O., van Melick H.H., Hooft L., Bosch J.R., Reitsma H.B., Barentsz J.O., et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur. Urol. 2017; 71(4): 517–31. https://doi.org/10.1016/j.eururo.2016.07.041Friedl A., Schneeweiss J., Sevcenco S., Eredics K., Kunit T., Susani M., et al. In-bore 3.0-T magnetic resonance imaging-guided transrectal targeted prostate biopsy in a repeat biopsy population: diagnostic performance, complications, and learning curve. Eur. Urol. 2018; 114: 139-46. https://doi.org/10.1016/j.urology.2017.12.032Friedl A., Schneeweiss J., Sevcenco S., Eredics K., Kunit T., Susani M., et al. In-bore 3.0-T magnetic resonance imaging-guided transrectal targeted prostate biopsy in a repeat biopsy population: diagnostic performance, complications, and learning curve. Eur. Urol. 2018; 114: 139–46. https://doi.org/10.1016/j.urology.2017.12.032Baco E., Ukimura O., Rud E., Vlatkovic L., Svindland A., Aron M., et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur. Urol. 2015; 67(4): 787-94. https://doi.org/10.1016/j.eururo.2014.08.077Baco E., Ukimura O., Rud E., Vlatkovic L., Svindland A., Aron M., et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur. Urol. 2015; 67(4): 787–94. https://doi.org/ 10.1016/j.eururo.2014.08.077Kasivisvanathan V., Rannikko A.S., Borghi M., Panebianco V., Mynderse L.A., Vaarala M.H., et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 2018; 378(19): 1767-77. https://doi.org/10.1056/NEJMoa1801993Kasivisvanathan V., Rannikko A.S., Borghi M., Panebianco V., Mynderse L.A., Vaarala M.H., et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 2018; 378(19): 1767–77. https://doi.org/10.1056/NEJMoa1801993Wegelin O., van Melick H.H., Hooft L., Bosch J.L., Reitsma H.B., Barentsz J.O., et al.Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: A systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration? Is there a preferred technique. Eur. Urol. 2017; 71(4): 517-31. https://doi.org/10.1016/j.eururo.2016.07.041Wegelin O., van Melick H.H., Hooft L., Bosch J.L., Reitsma H.B., Barentsz J.O., et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: A systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration? Is there a preferred technique. Eur. Urol. 2017; 71(4): 517–31. https://doi.org/10.1016/j.eururo.2016.07.041Norris J.M., Kinnaird A., Margolis D.J., Padhani A.R., Walz J., Kasivisvanathan V. Developments in MRI-targeted prostate biopsy. Curr. Opin. Urol. 2020; 30(1): 1-8. https://doi.org/10.1097/MOU.0000000000000683Norris J.M., Kinnaird A., Margolis D.J., Padhani A.R., Walz J., Kasivisvanathan V. Developments in MRI-targeted prostate biopsy. Curr. Opin. Urol. 2020; 30(1): 1–8. https://doi.org/10.1097/MOU.0000000000000683Dickinson L., Hu Y., Ahmed H.U., Allen C., Kirham A.P., Emberton M., et al. Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system. Br. J. Urol. 2013; 112(5): 594-601. https://doi.org/10.1111/bju.12223Dickinson L., Hu Y., Ahmed H.U., Allen C., Kirham A.P., Emberton M., et al. Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system. Br. J. Urol. 2013; 112(5): 594–601. https://doi.org/10.1111/bju.12223Schiffmann J., Tennstedt P., Fischer J., Tian Z., Beyer B., Boehm K., et al. Does HistoScanning predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate. World J. Urol. 2014; 32(4): 925-30. https://doi.org/10.1007/s00345-014-1330-5Schiffmann J., Tennstedt P., Fischer J., Tian Z., Beyer B., Boehm K., et al. Does HistoScanning predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate. World J. Urol. 2014; 32(4): 925–30. https://doi.org/10.1007/s00345-014-1330-5Glybochko P.V., Alyaev Y.G., Amosov A.V., Nir D., Winkler M., Ganzha M.T. Evaluation of prostate HistoScanning as a method for targeted biopsy in routine practice. Eur. Urol. 2017; 5(2): 179-85. https://doi.org/10.1016/j.euf.2017.07.001Glybochko P.V., Alyaev Y.G., Amosov A.V., Nir D., Winkler M., Ganzha M.T. Evaluation of prostate HistoScanning as a method for targeted biopsy in routine practice. Eur. Urol. 2017; 5(2): 179–85. https://doi.org/10.1016/j.euf.2017.07.001Simmons L.A., Autier P., Zat’ura F., Braecman J., Peltier A., Romic A., et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™). Br. J. Urol. 2012; 110(1): 28-35. https://doi.org/10.1111/j.1464-410X.2011.10734.xSimmons L.A., Autier P., Zat’ura F., Braecman J., Peltier A., Romic A., et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™). Br. J. Urol. 2012; 110(1): 28–35. https://doi.org/10.1111/j.1464-410X.2011.10734.xФедорова А.А., Амосов В.А., Говоров А.В., Зубарев А.В., Васильев А.О., Прилепская Е.А. и др. Гистосканирование предстательной железы. Методические рекомендации № 41. М.: АБВ-пресс; 2019Fedorova A.A., Amosov V.A., Govorov A.V., Zubarev A.V., Vasil’ev A.O., Prilepskaya E.A., et al. Prostate Histoscanning. Educational and Methodical Manual № 41 [Gistoskanirovanie predstatel’noy zhelezy. Metodicheskie rekomendatsii № 41]. Moscow: ABV-press; 2019. (in Russian)Sivaraman A., Sanchez-Salas R., Barret E., Macek P., Validre P., Gallano M., et al. Prostate HistoScanning true targeting guided prostate biopsy: initial clinical experience. World J. Urol. 2014; 33(10): 1475-9. https://doi.org/10.1007/s00345-014-1434-ySivaraman A., Sanchez-Salas R., Barret E., Macek P., Validre P., Gallano M., et al. Prostate HistoScanning true targeting guided prostate biopsy: initial clinical experience. World J. Urol. 2014; 33(10): 1475–9. https://doi.org/10.1007/s00345-014-1434-yJaved S., Chadwick E., Edwards A.A., Beveridge S., Laing R., Bott S., et al. Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. Br. J. Urol. 2014; 114(4): 541-8. https://doi.org/10.1111/bju.12568Javed S., Chadwick E., Edwards A.A., Beveridge S., Laing R., Bott S., et al. Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. Br. J. Urol. 2014; 114(4): 541–8. https://doi.org/10.1111/bju.12568Stroman L., Cathcart P., Lamb A., Challacombe B., Popert R. A cross-section of UK prostate cancer diagnostics during the coronavirus disease 2019 (COVID-19) era - a shifting paradigm? Br. J. Urol. 2021; 127(1): 30-4. https://doi.org/10.1111/bju.15259Stroman L., Cathcart P., Lamb A., Challacombe B., Popert R. A cross-section of UK prostate cancer diagnostics during the coronavirus disease 2019 (COVID-19) era – a shifting paradigm? Br. J. Urol. 2021; 127(1): 30–4. https://doi.org/10.1111/bju.15259

The authors declare that there are no conflicts of interest present.